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Abstract
Introduction: Lymphocyte apoptosis and monocyte dysfunction play a pivotal role in sepsis-induced
immunosuppression. Programmed death-1 (PD1) and its ligand programmed death ligand-1 (PD-L1) exert
inhibitory function by regulating the balance among T cell activation, tolerance, and immunopathology. PD-1
deficiency or blockade has been shown to improve survival in murine sepsis. However, PD-L1 and PD-1 differ in
their expression patterns and the role of PD-L1 in sepsis-induced immunosuppression is still unknown.
Methods: Sepsis was induced in adult C57BL/6 male mice via cecal ligation and puncture (CLP). The expression of
PD-1 and PD-L1 expression on peripheral T cells, B cells and monocytes were measured 24 hours after CLP or
sham surgery. Additionally, the effects of anti-PD-L1 antibody on lymphocyte number, apoptosis of spleen and
thymus, activities of caspase-8 and caspase-9, cytokine production, bacterial clearance, and survival were
determined.
Results: Expression of PD-1 on T cells, B cells and monocytes and PD-L1 on B cells and monocytes were up-
regulated in septic animals compared to sham-operated controls. PD-L1 blockade significantly improved survival of
CLP mice. Anti-PD-L1 antibody administration prevented sepsis-induced depletion of lymphocytes, increased tumor
necrosis factor (TNF)-a and interleukin (IL)-6 production, decreased IL-10 production, and enhanced bacterial
clearance.
Conclusions: PD-L1 blockade exerts a protective effect on sepsis at least partly by inhibiting lymphocyte apoptosis
and reversing monocyte dysfunction. Anti-PD-L1 antibody administration may be a promising therapeutic strategy
for sepsis-induced immunosuppression.
Introduction
Sepsis, a systemic inflammatory response to infection,
results in the death of more than 210,000 people in the
United States annually [1]; it remains the leading cause
of death in critical ill patients [2]. Because critical care
treatment is becoming expensive, understanding the
molecular mechanisms underlying the development of
sepsis is important in identifying new therapeutic
strategies.
Protracted immunosuppression caused by impaired
pathogen clearance after primary infection or suscept-
ibility to secondary infection may contribute to the high
rates of morbidity and mortality associated with sepsis
[3,4]. Accumulating evidence [5-7] suggests the pivotal
role of apoptosis in sepsis-induced immunosuppression.
Numerous studies have shown that the numbers of per-
ipheral and splenic lymphocytes are reduced during sep-
sis in both humans and animals [8,9]. Apoptosis is
known to be mainly responsible for decreased lympho-
cyte numbers, and the extent of lymphocyte apoptosis
correlates with the severity of sepsis [10]. In multiple
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remarkably improved by inhibiting lymphocyte apoptosis
by using selective caspase inhibitors [11,12]; altering
proapoptotic/antiapoptotic protein expression [13,14];
treatment with survival promoting cytokines such as
interleukin (IL)-7 [15] and/or IL-15 [16]; and modulat-
ing costimulatory receptors [17,18].
Monocytes play an essential role in innate immune
defense against microbial infection. rapidly exhibit an
impaired production of proinflammatory cytokines in
response to additional bacterial challenge [19], and a
reduced antigen presentation capacity likely due to their
decreased expression of human leukocyte antigen(locus)
DR (HLA-DR) [20]. Such monocytic deactivation indi-
cates a state of globally impaired immune functions and
correlates with poor clinical outcome in critically ill
patients.
Programmed death-1 (PD-1) is a newly defined co-inhi-
bitory receptor whose expression can be induced, primar-
ily on the cell surface of activated CD4 and CD8 T cells.
PD-1 has two main ligands: PD-L1 (B7-H1) and PD-L2
(B7-DC). PD-L1 is broadly expressed on hematopoietic
and non-hematopoietic cells, including T cells, B cells,
dendritic cells (DCs), macrophages, endothelial cells,
epithelial cells, pancreatic islet cells, and fibroblastic reti-
cular cells [21]. PD-1 and its ligand exert inhibitory effects
in the setting of persistent antigenic stimulation by regu-
lating the balance among T cell activation, tolerance, and
immunopathology. The PD-1/PD-L1 pathway plays a criti-
cal role in the regulation of autoimmunity, tumor immu-
nity, transplantation immunity, allergy, immune privilege,
and ischemia/reperfusion injury [22]. Recent findings sug-
gest that the PD-1/PD-L1 pathway plays an important role
in the interaction between host and pathogenic microbes
that evolved to resist immune responses. Those pathogens
include viruses [23], certain bacteria [24], fungi [25], and
some worms [26]. Studies using PD-L1-knockout mice
support the finding that PD-L1 is the primary regulatory
counter receptor for the inhibitory function of PD-1 [27].
Many studies showed that PD-L1 antagonism can block
the interaction of PD-1 and PD-L1 [28-31]. Hence, we
hypothesized that the blockade of PD-L1 using anti-PD-L1
antibody would improve survival in sepsis. The purpose of
this study was to elucidate the effect of PD-L1 blockade
caused by an antagonistic antibody to PD-L1 on survival
in a murine cecal ligation and puncture (CLP) model of
sepsis. In addition, this study attempted to determine the
potential mechanism underlyin gt h ep u t a t i v eb e n e f i c i a l
effect of PD-L1 antagonism in sepsis.
Materials and methods
CLP model of sepsis
All experiments were approved by the Institutional Ani-
mal Care and Use Committee. Adult 8- to 10-week-old
(22 to 30 g) C57BL/6 male mice were purchased from
the Animals Experimentation Center of Second Military
Medical University. CLP-induced polymicrobial sepsis
was performed as described previously [15]. Briefly,
mice were anesthetized with isofluorane and a midline
abdominal incision was made. The cecum was mobi-
lized, ligated below the ileocecal valve, and punctured
t w i c ew i t ha2 2g a u g en e e d l et oi n d u c ep o l y m i c r o b i a l
peritonitis. The abdominal wall was closed in two layers.
Sham-operated mice underwent the same procedure,
including opening the peritoneum and exposing the
bowel, but without ligation and needle perforation of
the cecum. After surgery, the mice were injected with 1
mL physiologic saline solution for fluid resuscitation. All
mice had unlimited access to food and water both pre-
and postoperatively.
PD-1 and PD-L1 expression on peripheral T cells, B cells
and monocytes
Mice were euthanized 24 h after CLP or sham-operated
surgery, and blood was obtained to analyze expression
of PD-1 and PD-L1. After erythrocytes were lysed with
lysing solution (BD Bioscience San Jose, CA, USA), cells
were stained with fluorochrome-conjugated anti-CD3,
anti-CD19, anti-CD11b, anti-PD-1 or anti-PD-L1 antibo-
dies. Flow cytometric analysis was performed on a
MACS Quant (Miltenyi Biotech, Bergisch Gladbach,
Germany) using Flowjo software version 7.6 (Tree Star,
Ashland, OR, USA). For flow cytometric analysis, we
first gated on a lymphocyte/monocyte population in
FSC/SSC, then T cells, B cells or monocytes were gated
on CD3, CD19 or CD11b-positive cells, respectively.
Abs were purchased from eBioscience (San Jose, CA,
USA): CD3-PerCP-Cy5.5 (Clone: 145-2C11), CD19-PE-
Cy7 (Clone: 1D3), CD11b-APC (Clone: M1/70), PD-1-
PE (Clone: J43), PD-L1-PE (Clone: MIH5).
Effect of PD-L1 blockade on the survival of septic mice
In order to compare the effect of anti-PD-L1 antibody
administration at different time-points on survival, treat-
ment with the antibody before or after CLP was used. To
confirm the in vivo protective effect of PD-L1 blockade
on sepsis, C57BL/6 male mice were intraperitoneally
injected with anti-PD-L1 antibody (50 μg/mouse), isotype
antibody (50 μg/mouse), or saline 24 h before CLP, and
survival rates were assessed over the subsequent eight
days. To assess the potential therapeutic effect of PD-L1
blockade, mice that underwent CLP were subsequently
randomized to receive intraperitoneal anti-PD-L1 anti-
body (50 μg/mouse), isotype control antibody (50 μg/
mouse) or saline 3 h after CLP surgery. Survival was over
the subsequent eight days. All mice were subcutaneously
administered 1 mL normal saline within 30 minutes after
CLP and allowed free access to food and water.
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and thymus
Mice that underwent CLP were randomized to intraperi-
toneally receive anti-PD-L1 antibody (50 μg/mouse), iso-
type control antibody (50 μg/mouse), or saline after CLP
surgery. The blood, spleen and thymus of the septic and
sham-operated mice were harvested 24 h after CLP. The
total cell number was counted after lysis of erythrocytes
(for spleen and thymus, single-cell suspension was pre-
pared). Cells were also stained with fluorochrome-conju-
gated antibodies to cell subset-specific surface markers
(CD3 for T cells and CD19 for B cells). Lymphocyte
numbers were calculated by obtaining total cell count
and lymphocyte subgroup percentage by FACS analysis.
Quantification of apoptosis in the spleen and thymus
The spleen and thymus were harvested from septic and
sham-operated mice 24 h after surgery and treatment,
and fixed with 10% buffered formalin. Terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) staining was performed using the ApopTag
Plus Peroxidase In Situ Apoptosis Detection Kit (Chemi-
con Billerica, MA, USA) according to the manufacturer’s
instructions. In brief, sections were incubated in equili-
bration buffer for 10 minutes and then terminal deoxynu-
cleotidyl transferase and dUTP-digoxigenin were added
to the sections and incubated in a 37°C humidified cham-
ber for 1 h. The reaction was then stopped and the slices
were washed and incubated with anti-digoxigenin-peroxi-
dase solution, colorized with DAB/H2O2,a n dc o u n t e r -
stained with bis-benzamide. From each specimen, two
sections were initially examined under light microscopy
at low magnification (×100). Five fields per section were
randomly examined at a higher magnification (×400).
Two investigators examined the samples microscopically
in a blinded fashion. The percentage of the TUNEL-posi-
tive cells was used to determine the apoptosis rate. For
detection of T cells apoptosis and activities of caspase-8
and caspase-9 in the thymus, thymuses from CLP or
sham-operated mice were harvested 24 h after surgery
and treatment. A single-cell suspension was prepared.
CD3
+ T cells were stained with annexin V and propidium
iodide (PI) for apoptosis measurement and stained for
active caspase-8 using IEHD-FMK (BioVision, Mountain
View, CA, USA), and for active caspase-9 using LEHD-
FMK (BioVision, USA) according to the manufacturer’s
instructions.
Cytokine analysis and bacterial clearance
Plasma from CLP or sham-operated mice was harvested
24 h after surgery and treatment. Concentrations of
tumor necrosis factor (TNF)-a, IL-6, and IL-10 were
measured using murine enzyme-linked immunosorbent
assay (ELISA) kit (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’si n s t r u c t i o n s .F o r
bacterial clearance, blood and peritoneal lavage fluid
samples were collected 24 h after surgery and treatment.
Blood was collected by heart puncture after isoflurane
anesthesia. Peritoneal lavage fluid was harvested after
injecting 2 mL PBS into the peritoneum and serial dilu-
tion in samples was serially diluted to 10-, 100-, or
1,000-fold in 500 μL PBS. A 100 μL aliquot of each dilu-
tion was spread on a tryptic soy agar (TSA) blood agar
plate. All plates were incubated at 37°C for 24 h. Colo-
nies were counted and expressed as colony forming
units (CFUs)/mL for all the samples.
Statistical analysis
Data reported are the mean (SEM). All statistical ana-
lyses were performed using Prism 4.0 (GraphPad Soft-
ware, La Jolla, CA, USA). Survival of the two subgroups
was estimated by Kaplan-Meier analysis; comparisons
were performed by the log-rank test. All comparisons
among groups were performed by Mann-Whitney analy-
sis of variance. For multigroup analysis, intergroup com-
parisons were performed by Dunn’s test. Significance
was accepted at P < 0.05.
Results
Upregulation of PD-1 and PD-L1 on T cells, B cells and
monocytes during sepsis
Expression of PD-1 on T cells (CD3
+), B cells (CD19
+)
and monocytes (CD11b
+) increased significantly in CLP
mice compared with sham mice (P <0 . 0 5a n dP <0 . 0 1 ,
respectively) (Figure 1A, C). Expression of PD-L1 on B
cells and monocytes were also upregulated in septic ani-
mals (P < 0.01), whereas PD-L1 expression on T cells
was not altered significantly (Figure 1B, D).
PD-L1 blockade improves survival of murine sepsis
Mice pretreated with anti-PD-L1 antibody for 24 h
before CLP showed an improved eight-day survival
( 7 0 . 0 % )c o m p a r e dw i t ht h a to fm i c ep r e t r e a t e dw i t h
saline (7.8%; P < 0.05) or those pretreated with isotype
control antibody (16.6%; P <0 . 0 5 ;F i g u r e2 A ) .M i c e
treated with anti-PD-L1 antibody 3 h after CLP also
showed an improved eight-day survival (50.0%, P < 0.05;
Figure 2B). No statistical difference was shown between
mice treated with isotype controls or with saline.
PD-L1 blockade decreases lymphocyte apoptosis in
spleen and thymus of septic mice in situ
In the spleen of sham-operated mice, physiologic
TUNEL-positive cells, which were morphologically iden-
tical to lymphocytes, were sporadically found, and their
number increased markedly after induction of sepsis by
CLP. However, the CLP mice that were administered
anti-PD-L1 antibody showed decreased numbers of
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number of apoptotic lymphocytes in the thymus of mice
treated with anti-PD-L1 antibody compared with those
in the mice treated with CLP-only or in those treated
with the isotype antibody (Figure 3A, B).
PD-L1 blockade increases lymphocyte number in
peripheral blood, spleen and thymus
As expected, the numbers of total white blood cells and
lymphocytes were higher in the blood of the PD-L1
blockade group than those in the CLP-only or isotype
Figure 1 PD-1 and PD-L1 expression on T cells, B cells and monocytes. (A) Percent of PD-1 expression on CD3
+ T cells, CD19
+ B cells and
CD11b
+ monocytes 24 h after CLP (n = 5) or sham control surgery (n = 5). (B) Percent of PD-L1 expression on CD3
+ T cells, CD19
+B cells and
CD11b
+ monocytes 24 h after CLP (n = 5) or sham control surgery (n = 5), (C, D) Representative PD-1 and PD-L1 expression on T, B cells and
monocytes detected by flow cytometry. * P< 0.05, ** P< 0.01.
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the spleens and thymuses (Figure 4).
Both the extrinsic death receptor pathway and the
intrinsic mitochondrial-mediated pathway contribute to
decreased lymphocyte apoptosis in vivo
Data showed that PD-L1 blockade decreased the apoptosis
of CD3
+ T cells in the thymus (Figure 5A, D). PD-L1
blockade also decreased the activity of caspase-8 to
approximately 30% of CLP level (Figure 5B, E). Similar
results were also observed for active caspase-9 (Figure 5C,
F). These data indicate that both the extrinsic death recep-
tor pathway and the intrinsic pathway contributed to the
decreased lymphocyte apoptosis in vivo. This is consistent
with the widely accepted idea that the extrinsic and the
intrinsic apoptotic pathways are intimately connected.
Cytokines levels and bacterial clearance
PD-L1 blockade significantly increased the expression of
TNF-a, IL-6 and decreased the level of IL-10 in CLP
murine plasma (Figure 6A, B, C). Mice that received
anti-PD-L1 antibody showed a deceased bacterial bur-
den in both blood and peritoneal lavage fluid compared
with that in the mice treated with the isotype antibody
or those treated with saline (Figure 6D, E).
Discussion
Lymphocytes and monocytes are thought to be critical
in mediating both apoptosis and cytokine release during
sepsis and the PD-1/PD-L1 pathway is critical in T cell
co-stimulatory signal regulation [21,22]. To explore the
role of PD-L1 in sepsis, we initially investigated PD-L1
and PD-1 expression on T cells, B cells, and monocytes
in response to sepsis. We found a significant up-regula-
tion of PD-L1 expression on monocytes and B cell at
24 h post-CLP. Our finding of increased PD-1 expression
is consistent with that of the study by Huang et al. [32].
Our study indicated that besides PD-1, PD-L1 expression
was also up-regulated on monocyte during sepsis, sug-
gesting that PD-L1 may play a role in the process.
PD-1 deficiency or anti-PD-1 antibody has been shown
to improve survival in murine sepsis models [32,33]. Our
findings suggest that besides PD-1 blockade, anti-PD-L1
antibody administration significantly improved survival
of CLP mice, and decreased T cell apoptosis and
improved monocyte dysfunction, which may contribute
to the beneficial effect of PD-L1 blockade.
Several studies have shown that PD-L1 blockade aug-
mented T cell functions in chronic virus infection
[27,34]. However, our study did not suggest that PD-L1
blockade had significant effects on CD4
+ and CD8
+ T
cell functions, including proliferation and interferon-g or
IL-2 production (data not shown). Our data show that
PD-L1 blockade decreased lymphocyte apoptosis in the
spleens and thymuses of septic mice in situ, increased
lymphocyte number in peripheral blood, spleens and
thymuses, indicating that like PD-1 blockade, anti-PD-
L1 antibody administration could indeed inhibit T cell
apoptosis. We further show that both the extrinsic
death receptor pathway and the intrinsic mitochondrial-
mediated pathway contributed to decreased lymphocyte
apoptosis in vivo. Of note, we found that PD-L1 block-
ade also decreased apoptosis of bronchial epithelial cells
and alveolar epithelial cell in lungs (data not shown),
suggesting perhaps other cell targets involved in the
beneficial effect of PD-L1 blockade.
Figure 2 Anti-PD-L1 antibody administration protects mice from sepsis-induced lethality. (A) Anti-PD-L1 antibody pretreatment protected
mice from CLP. CLP mice were given 50 μg anti-PD-L1 antibody (n = 18), 50 μg isotype control antibody (n = 12) or 0.2 mL saline
intraperitoneally 24 h before CLP surgery. (B) Effect of intraperitoneal anti-PD-L1 antibody treatment given 3 h after CLP. CLP mice were given
50 μg anti-PD-L1 antibody (n = 18), 50 μg isotype control antibody (n = 12) or 0.2 mL saline (n = 12) intraperitoneally 3 h after CLP. Survival was
monitored for eight days. Data are shown as the survival percent of animals. *P< 0.05.
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incomplete, and T cell apoptosis remains to some
degree after PD-L1 pathway blockade, implicating the
involvement of other regulatory pathways in sepsis-
induced T cell apoptosis.
During the inflammatory response, monocytes present
antigens by means of expression of human leukocyte
antigen (HLA) receptors and secrete proinflammatory
cytokines to amplify the immune response. Multiple stu-
dies have demonstrated that during sepsis-induced
Figure 3 PD-L1 blockade inhibits cell apoptosis in spleen and thymus. Mice underwent a sham procedure, CLP, CLP plus anti-PD-L1 or
isotype administration (n = 5 for each group). Spleen and thymus were harvested 24 h after surgery. (A) Representative sections analyzed by an
in situ TUNEL assay. (B) Percent of the TUNEL-positive cells is used to show the cell apoptosis in spleen and thymus of the 4 groups. * P< 0.05.
Figure 4 Cell numbers in blood (A), spleen (B) and thymus (C). Mice underwent a sham procedure, CLP, CLP plus anti-PD-L1 administration,
or CLP plus isotype administration (n = 5 for each group). Blood, thymus and spleen were harvested 24 h after surgery. The total cell number
was counted after lysis of erythrocytes (for spleen and thymus, preparation of a single-cell suspension was required). Lymphocyte numbers (CD3
+ T cells, CD3- T cells, CD19+ B cells) were calculated by the total number and percent of lymphocyte subgroups resulting from FACS analysis,
respectively. * P< 0.05.
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Page 6 of 9Figure 5 Both extrinsic and intrinsic pathways contribute to decreased lymphocyte apoptosis in vivo. Mice underwent sham procedure,
CLP, CLP plus anti-PD-L1 antibody administration, or CLP plus isotype administration. Thymus was harvested 24 h after surgery and stained for
annexin V and propidium iodide (PI) (A, D) or FITC-labeled IEHD-FMK (B, E) or LEHD-FMK (C, F) which can irreversibly binds to activated
caspase-8 or activated caspase-9. (D), (E), and (F) are the representative flow cytometry dot plots. Values in the upper right quadrant indicate
the percent of apoptotic cells, caspase-8 or caspase-9 positive cells, respectively. * P< 0.05.
Figure 6 Levels of plasma cytokines and bacterial clearance. Mice underwent a sham procedure, CLP, CLP plus anti-PD-L1 administration, or
CLP plus isotype control administration (n = 5 for each group). Levels of TNF-a (A),I L - 6(B) and IL-10 (C) were measured 24 h after surgery. Treatment
with anti-PDL1 antibody improves bacterial clearance in septic mice. Mice that received anti-PD-L1 antibody exhibited a deceased bacterial burden in
peritoneal lavage fluid in comparison with mice that received isotype antibody or saline (D), Mice that received anti-PD-L1 antibody exhibited a
deceased bacterial burden in blood in comparison with mice that received isotype antibody or saline (E),*P < 0.05, ** P <0 . 0 1 .
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and down-regulate expression of HLA receptors. This
impaired function of monocytes generally predicts
increased risk of secondary infection and poor prognosis
[35,36]. In our study, we found dramatic up-regulation
of PD-L1 on monocytes in CLP mice, and this up-regu-
lation was likely associated with monocyte dysfunction.
PD-L1 blockade exhibited a markedly decreased IL-10,
elevated TNF-a and IL-6 levels in plasma as well as a
decreased bacterial burden both in blood and peritoneal
lavage fluid. However, PD-1 blockade did not alter
plasma cytokine levels [33].
There is a balance between pro-inflammatory and
anti-inflammatory responses during sepsis. Both
responses occur simultaneously during the early phase
of the disease. During the stage of sepsis-induced immu-
nosuppression, there is an excessive anti-inflammatory
response named compensatory anti-inflammatory
response syndrome (CARS). CARS has a distinct set of
cytokines and cellular responses characterized by the
reduction of lymphocytes, decreased cytokine response
of monocytes to stimulation, decreased numbers of
human leukocyte antigen (HLA) antigen-presenting
receptors on monocytes, and expression of anti-inflam-
matory cytokines such as IL-10 [35]. Our study demon-
strated that PD-L1 may play a vital role in the balance
of pro-inflammatory and anti-inflammatory responses
during sepsis. In addition to a decrease of apoptosis in
T cells, PD-L1 blockade could reverse monocyte dys-
function by modulating cytokine production.
Conclusions
PD-L1 blockade exerts a protective effect on sepsis, at
least partly by inhibiting lymphocyte apoptosis and
reversing monocyte dysfunction by modulating cytokine
production. Anti-PD-L1 antibody administration may be
a promising therapeutic strategy for sepsis-induced
immunosuppression.
Key messages
￿ Expression of PD-1 on T cells, B cells and mono-
cytes and PD-L1 on B cells and monocytes were up-
regulated in septic animals.
￿ PD-L1 blockade significantly improved survival of
CLP mice.
￿ Anti-PD-L1 antibody administration prevented sep-
sis-induced depletion of lymphocytes, increased TNF-a
and IL-6 production, decreased IL-10 production, and
enhanced bacterial clearance.
￿ Anti-PD-L1 antibody administration may be a pro-
mising therapeutic strategy for sepsis-induced immuno-
suppression.
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